VCRE logo

VICORE PHARMA HOLDING AB ADR

VCRENASDAQ
πŸ† #3236 by market capEarnings Feb 25 Β· PostUS Equity
β€”β€”
Quote unavailable
πŸ””
Track VCRE
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$275M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-48.4%
Declining
πŸ“ŠGross Margin
360.3%
High
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
700.3x
Expensive
Otter Score
36
Weak
No chart data available for VCRE.

Trading Snapshot

Day Range
β€”
52-Week Range
β€”
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
281.6M
Next Earnings
2027-02-25

Fundamentals Snapshot

Annual Revenue
$4M
Last Q Revenue
$228,246
P/E Ratio
β€”
P/S Ratio
700.3x
EPS (TTM)
β€”
Dividend Yield
β€”
Dilution (1yr)
+18.4%
VCRE logo

VICORE PHARMA HOLDING AB ADR

VCRE
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$4Mβ–Ό βˆ’96.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%β–² +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$454Mβ–² +138.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$376Mβ–² +127.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
25.6Mβ–² +18.4% YoY
StockOtter Β· stockotter.space

About VICORE PHARMA HOLDING AB ADR

Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. Its drug development programs include VP01, VP02, VP03, and VP04. The company was founded in 2000 sand is headquartered in Stockholm, Sweden.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
36/100

Analyst Ratings

β“˜
Consensus
Buy
14 analysts
Strong Buy6
Buy7
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

News unavailable.